NCT05283083View on ClinicalTrials.gov

Decatecholaminisation of Septic Shock With Dexmedetomidine and In-hospital Mortality

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

March 1, 2023

Conditions
Septic ShockSepsis
Interventions
DRUG

Dexmedetomidine

A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.

Trial Locations (1)

35516

Mansoura University Hospitals, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER